Royal Sense FY26 Revenue Jumps to Rs 103 Crore; Amalgamation Announced

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Royal Sense FY26 Revenue Jumps to Rs 103 Crore; Amalgamation Announced

Royal Sense reported a significant rise in FY26 consolidated revenue to Rs 103.38 crore, up from Rs 61.73 crore in the previous year. Profit after tax also saw a modest increase to Rs 7.15 crore. The company announced the upcoming amalgamation of TTG Innovations, which holds a Delhi government tender expected to boost annual sales by roughly Rs 100 crore. Additionally, the firm is expanding its retail footprint and proposing an ESOP scheme for employees.

Royal Sense FY26 Revenue Hits Rs 103 Crore

Revenue from operations reached Rs 103.38 crore for FY26 compared to Rs 61.73 crore in FY25.
Profit After Tax rose to Rs 7.15 crore in FY26 from Rs 633.12 lakh in the previous year.

Reader Takeaway: Strong top-line growth is bolstered by a major upcoming amalgamation, though operational integration remains a key factor.

What just happened

Royal Sense has released its consolidated financial performance for the year ended March 31, 2026, alongside a series of strategic corporate announcements. The company is actively pursuing growth through the amalgamation of TTG Innovations Private Limited, which has already received a 'no adverse observation' letter from BSE. The company has filed the first motion application with the NCLT for this merger.

Why this matters

The acquisition of TTG Innovations is a major strategic move. The entity currently holds a tender from the Delhi government that the Board estimates will contribute an additional Rs 100 crore in annual sales once the merger is complete. This effectively signals a potential doubling of the current scale for Royal Sense.

What changes now

Shareholders will vote on key items at the 3rd Annual General Meeting on September 28, 2026. This includes the re-appointment of Managing Director Rishabh Arora, an increase in authorized share capital from Rs 10 crore to Rs 20 crore, and the implementation of the 'RSL ESOP Scheme 2026' to provide equity incentives representing up to 10% of paid-up capital.

Corporate Expansion

Operationally, the company is scaling its infrastructure. This includes the launch of the first retail pharmacy counter under the Stergic Pharmacy brand and the lease of a new warehouse facility in Sonipat, Haryana, to strengthen its distribution network.

Risks to watch

Investors should monitor the NCLT process for the finalization of the TTG Innovations merger and the successful execution of the government tender. Changes in leadership, specifically regarding the recent turnover in the Company Secretary role, should also be tracked for organizational stability.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.